glp-1 dementia study Frontiers Advances in Clinical and Experimental

[DOI] [PMC free article] [PubMed] [Google Scholar] 22.Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al

In recent years, the pharmaceutical landscape has seen the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as semaglutide and tirzepatide, offering promising outcomes in weight reduction for those struggling with obesity

Those compounded drugs were only supposed to be broadly offered while the popular brand-name drugs were in shortage

However, while the clinical results with semaglutide support indications for treatment of obesity per s (Wegovy R ) as well as T2D (Ozempic R ), weight reduction with these agents remains considerably less than the best surgical results, and is often only a fraction of what most patients require for correction of the co-morbidities of increased body weight

Maturity-onset diabetes of the young: what do clinicians need to know